Decoding 8 Analyst Evaluations For Neurocrine Biosciences
Portfolio Pulse from Benzinga Insights
Neurocrine Biosciences (NASDAQ:NBIX) has been evaluated by 8 analysts over the past three months, showing a mix of bullish to bearish sentiments. The average 12-month price target is $151.88, marking a 7.72% increase from the previous target. Analysts from firms like Oppenheimer and JP Morgan have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Neurocrine Biosciences, a pharmaceutical company, has shown a 25.05% revenue growth rate as of December 31, 2023, but faces challenges in profitability and efficiency metrics.
March 13, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences has received mixed analyst ratings with an updated average 12-month price target of $151.88, indicating a positive sentiment. The company's significant revenue growth contrasts with challenges in profitability and efficiency.
The mixed analyst ratings with a positive adjustment in the average 12-month price target suggest a cautiously optimistic outlook for NBIX. The significant revenue growth is a strong positive factor, although concerns about profitability and efficiency metrics could temper investor enthusiasm. The adjustments in ratings and price targets by analysts from reputable firms further underscore the relevance of these evaluations for potential investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100